Intercept Pharmaceuticals Stock Overreacts To Company Communiqué, Presents Buy Opportunity
- Intercept Pharmaceuticals saw yet another slump in its price.
- The company plans to boost revenue by capturing international markets.
- The company plans to boost revenue by capturing international markets.
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) stock suffered another setback as the company posted a letter it had sent to doctors about its Ocaliva product. The letter detailed out some rather stark adverse impact of overdosing on Ocaliva. As a result, the stock tanked more than 14 percent in a single day.
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.
An abridged version is available below to our investor members. Login or Subscribe here.